GANX — Gain Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1819411 ·
Last close
$1.78
Market Cap
$77.69M
52W High
$4.34
52W Low
$1.53
ADV30
364,030
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,681,652 | -4,675,571 | 15,421,939 | 13,084,144 | 4,129,908 |
| Mar 2026 | 0 | — | -5,353,545 | -5,608,732 | 18,738,464 | 16,539,222 | 4,731,487 |
| Dec 2025 | 0 | — | -4,466,023 | -4,537,581 | 22,818,975 | 20,837,628 | 4,254,227 |
| Sep 2025 | 0 | — | -4,785,777 | -5,284,373 | 10,971,680 | 8,807,353 | 5,062,250 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,371,432
Investing CF
$0
Financing CF
$26,455,009
CapEx
$-945
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.63
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-106,964,739
Inventory
—
Receivables
$994,609
ST Investments
$0
EBIT TTM
$-19,694,871
Pretax Income TTM
$-20,296,098
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -18,710,702 | -20,161,099 | 22,818,975 | 4,254,227 | 18,564,748 | -18,465,432 |
| Dec 2024 | 0 | -20,350,592 | -20,411,191 | 12,123,884 | 4,784,310 | 7,339,574 | -18,873,827 |
| Dec 2023 | 55,180 | -22,253,133 | -22,267,520 | 18,609,331 | 6,031,107 | 12,578,224 | -18,865,873 |
| Dec 2022 | 140,108 | -17,777,045 | -17,590,738 | 24,099,387 | 5,219,873 | 18,879,514 | -14,692,139 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.55
Max Pain — expiry 2026-10-16
max pain strike: $1.00 · spot: $1.77 · call oi: 3,215 · put oi: 522
Expected Move to 2026-10-16:
±$0.49
(27.97%) —
implied range
$1.27 –
$2.26
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OSTX | OS Therapies Inc | $77.70M | $1.66 | — |
| INCR | Intercure Ltd. | $78.17M | $5.21 | — |
| ZOMDF | Zomedica Corp. | $78.40M | $0.08 | — |
| LFVN | Lifevantage Corp | $78.42M | $6.26 | — |
| IBIO | iBio, Inc. | $76.53M | $1.19 | — |
News headlines (Yahoo Finance, 1h cache)
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
2026-09-17 11:00 · Yahoo
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
2026-08-25 11:00 · Yahoo
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
2026-07-16 11:00 · Yahoo
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
2026-06-29 20:05 · Yahoo
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
2026-06-10 11:00 · Yahoo
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
2026-05-27 04:34 · Yahoo
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
2026-05-22 00:58 · Yahoo
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
2026-05-11 11:00 · Yahoo
Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss
2026-05-11 13:51 · Yahoo
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
2026-04-24 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.